Live data · NADAC + Part D CY24 · reviewed daily

Adalimumab-Aqvh (YUSIMRY)

Tumor Necrosis Factor Blocker class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2023-07-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$1.0M in CY2024 Part D spend877 claims · 186 beneficiaries · 329 plans surveyed

Lowest NADAC
$604.15/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$604.15
Across all dosage forms in distribution.
Highest NADAC
$604.15
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Adalimumab-Aqvh used for?

Adalimumab-Aqvh is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Adalimumab-Aqvh?

No. Adalimumab-Aqvh is brand-only with no generic equivalents currently in market.

How much does my plan pay for Adalimumab-Aqvh?

Across 329 Part D plans, Adalimumab-Aqvh averages $604.15/unit (NADAC). Lowest available: $604.15/unit. Highest in distribution: $604.15/unit.

Is Adalimumab-Aqvh on the FDA shortage list?

No. Adalimumab-Aqvh is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.